



BIZENGRI® (zenocutuzumab-zbco) 20 mg/mL Injection for IV Us	se
Octiont Enrollment Form	

ratient Emoninent rom	[ <b>1</b>
SLIDDORT REQUIESTED (c	heck all that annly)

Insurance Verification	Patient Assistance	e 🔲 Claims Suppor
	-1	

age $1$ is to be completed by the patient. Page $2$ is t	to be completed by the healthcare provider.	Prior Authorization/Appeals For assistance, call (877) 353-8546, Monday-Friday,	• •
1 PATIENT INFORMATIO	N		
irst Name:		st Name:	
Address:			
Date of Birth:		none:	
Sex: Male Female	_	S Resident: Yes No	
SSN (last 4 digits)		nail:	
Patient Representative Name:		Patient Representative Pho	one:
2 FINANCIAL INFORMATI	ION (Only Required for Patien	Assistance request)	
Total Number of Household Men	nbers (including enrollee):	*Total Annual Gross Hou	sehold Income:
	the Enrollment Form which includes, be locumentation, please contact PTx Assist	not limited to 1040 form, W2, Social Se	curity Awards Letter, SSA 1099.
3 AUTHORIZATION TO U	SE AND DISCLOSE MY INFORM	ATION	
education and other support services, such as orm is true, correct, and complete, and I und boo) is no longer prescribed to me. I understa bersonal health, including information related on this enrollment form including my name, a o update the Program should any of the info eimburse for Bizengri®. I understand that che by signing this form, I authorize my treating dangents ("Partner Therapeutics"), my Protected including potential enrollment in the copay as bizengri or to obtain payment or other suppo formation and services related to Bizengri; a arrying out these activities, Partner Therapeutid-party patient assistance foundations. The	n below. By signing, I am enrolling in PTx Assist, th co-pay assistance and other forms of patient ass lerstand that PTx Assist ("the Program") assistance and other forms of patient ass lerstand that PTx Assist ("the Program") assistance and that in order for the Program to provide me value to my medical records and history, medications address, telephone number, social security number and second in the supplication form change, including anges in my health insurance coverage may imposed octor, my employer, and my health insurer to give dependent of the patient of the program of the patient and for the Patient ssistance program or Patient Assistance Program of Vital Discontinuation and (v) to assist with analyses related to the qual utics may share information about me with my doird parties may receive payment from Partner The or disclosed by Partner Therapeutics for any other second in the patient of the patient of the patient of the patient patient of the patient patient of the patient patient of the patient pati	ance (no-cost medication), offered now or in the will terminate if the Program becomes aware of a sasistance, it will need to obtain, review, use, an edical conditions and treatment, health insurance plan and/or group numbers (together if I become eligible for any benefit through a few my eligibility for the Program.  Deeple who work for and with Partner Therapeut apeutics (Partner Therapeutics, Inc.) to receive, presentative I identify below ("Patient Represer am eligible; (ii) to help verify, investigate, assist fillment; (iv) to provide me and/or my Patient Refficacy and safety of Bizengri, including patien tor, my employer, my health insurer, my pharm rapeutics to provide the services associated with	future. I attest that the information in this f any fraud or if Bizengri (zenocutuzumaband disclose information related to my nee coverage and the personal information er, "Protected Health Information"). I agree deral, state, or private program, which may utics, including its business partners and use and disclose my Protected Health neative"), about PTx Assist programs, t with or coordinate insurance coverage for Representative with educational materials, it access and treatment compliance. In nacy and/or pharmacists, and independent h the Program. I understand that my
information used or disclosed under this Authorization is valid for two (2) years from the right to change or end the Program at reatment of me or my eligibility for insurance will not apply to any information already used hat I will not be able to participate or receive By providing my phone number, I authorize I hame of Partner. Therapeutics products or secontacted by phone or text message as a con	efore is "de-identified." I also understand that Panorization may be re-disclosed by the recipient allow the date of my signature or until I am no long tany time without prior notification to me. I und be benefits. I further understand that I may revoked or disclosed pursuant to this Authorization. If I cassistance from PTx Assist.  PTx Assist to use autodialers or prerecorded and ervices and include details about my insurance condition of any purchase of Partner Therapeutics I de by calling Partner Therapeutics at (877) 353-3	may no longer be protected by federal or state participating in the Program, whichever is soon- tand that I may refuse to sign this form and tha his Authorization at any time by contacting the Fanot sign this form, or cancel (revoke) my Author ificial voice messages to contact me. I understa rage and doctor's name. I understand that I am ducts or enrollment. Message and data rates me	law. er. I understand that Partner Therapeutics it doing so will not affect my doctor's Program at 1-877-353-8546. The revocation rization later, I understand that this means and that these calls/texts may mention the inot required to consent to being
	ny Patient Representative about the information are providers or insurers have given to Partner T		stand that I have the right to see or copy
Signature:			
	ent Representative:		_
	TION – PLEASE CHECK HERE IF		
Payer Phone:	Group#	Policy ID:	
Policyholder Name:	Policyholder Date of Birth	Policyholder's Rela	ationship to Patient:
Secondary Medical Insurance:			
	Group#		
Policyholder Name:	Policyholder Date of Birth	Policyholder's Rela	ationship to Patient:
Patient First Name:		atient Last Name:	





Prescriber Name:	
Prescriber Address: City	: State: Zip Code:
Tax ID: NPI #	State License #
Treating Facility Name: Facility Ta	ax ID: Facility NPI #
Treating Facility Address:	
Treating Setting of Care: Hospital Inpatient Hospital Outpatient Other – Please Specify:	
Office Contact:	Phone:
Email:	Fax:
Preferred Method of Contact: Phone Email Fax (If unspo	ecified, then all communications will be sent via fax.)
For Copay Assistance Only: Payment will be in the form of Virtual Debit	Card (VDC) so please confirm email address:
For <b>Patient Assistance Program Only:</b> Bizengri will be shipped to the <b>Tr</b>	reating Facility Address above unless otherwise specified.
6 CLINICAL INFORMATION	
	nosis Code(s):
Has the Patient Tested NRG1 Positive? Yes No	
Prior Therapies Received:	
7 BIZENGRI PRESCRIPTION INFORMATION	
BIZENGRI® (zenocutuzumab-zbco) 20 mg/mL Injection for IV Use:	
	requency: everyweeks
	efill:
Additional Directions:	
Patient Allergies:	
Concurrent Medication:	offerd by DT. Assistant about the bar of the order
Patient will be pre-medicated prior to initial Bizengri infusion (not sup	plied by PTX Assist) with the following:
†Prescriber Certification and Authorization: By signing below, I am certifying that the inform signature certifies that I am a licensed practitioner eligible under state law to prescribe, recunderstand that Partner Therapeutics, Inc. reserves the right to modify or terminate PTx As responsible for filing claims and that the information provided by PTx Assist is for general repayer guidelines. I also understand that verification of insurance coverage is ultimately my many factors. Partner Therapeutics, through PTx Assist, does not represent or guarantee th made. I understand that Partner Therapeutics does not reimburse for claims denied by pay charge the patient or submit a claim to any third party for services related to my patient's E Program must only be used for the approved patient and may not be sold, traded, or return All final decisions on diagnosis, the need for treatment, and the appropriateness of Bizengi that I am under no obligation to prescribe any Partner Therapeutics drug and I have not recommend.	ceive, and administer the requested medication(s) listed on this enrollment form. I ssist at any time and without notice. I understand that Partner Therapeutics is not eference and informational purposes only and is based on my patient's health plan and responsibility as the healthcare provider and that reimbursement by payers is subject that payer reimbursement or any other payment or reimbursement of any kind will be vers. If my patient participates in the Patient Assistance Program, I certify that I will not Bizengri therapy. I understand that any product provided under the Patient Assistance ned for credit.  It for a particular patient rest with me as the patient's healthcare provider. I understance involved and will not receive any benefit from Partner Therapeutics for prescribing a g a valid and completed HIPAA Authorization form, from my patient to release the
Partner Therapeutics drug. I further verify that I have the required authorizations, including referenced medical and/or other patient information relating to my patient's treatment to Therapeutics and companies working with them, by mail, fax, e-mail, or telephone for the p withdraw my request for PTx Assist services at any time by calling (877) 353-8546.	purposes of managing and delivering services through the PTx Assist program. I may
Partner Therapeutics drug. I further verify that I have the required authorizations, including referenced medical and/or other patient information relating to my patient's treatment to Therapeutics and companies working with them, by mail, fax, e-mail, or telephone for the p withdraw my request for PTx Assist services at any time by calling (877) 353-8546.	purposes of managing and delivering services through the PTx Assist program. I may

Please see full Prescribing Information, including BOXED WARNING, for BIZENGRI (zenocutuzumab-zbco) 20 mg/mL Injection for IV Use at <a href="https://www.bizengri.com">www.bizengri.com</a>.

For general information about the PTx Assist Support Program, including financial criteria, please call (877) 353-8546, Monday through Friday, 9:00 am to 5:00 pm Eastern Time. Please fax the completed form to (855) 881-6864.



